,0,1
0,protein engineering,9.0
1,operational finance,8.857142857142858
2,balance sheet arrangements,8.774569402228977
3,natural regulator,8.75
4,executive officer,8.723809523809525
5,legal proceedings,8.714285714285715
6,sec requirement director,8.617647058823529
7,regulatory approval,8.563492063492063
8,regulatory approval,8.563492063492063
9,approval delay,8.563492063492063
10,balance sheet,8.560283687943263
11,retrospective application,8.545454545454545
12,licensed products,8.5
13,muscle disorder,8.5
14,audit,8.5
15,estate tax,8.47
16,stock unit,8.434994379917573
17,tgf beta,8.434782608695652
18,square foot,8.433333333333334
19,regulatory requirement,8.403361344537815
20,claim,8.4
21,property position,8.365384615384615
22,balance sheet,8.257328022918632
23,retrospective application,8.251336898395722
24,dilutive effect,8.25
25,retrospective application,8.194103194103194
26,ten year,8.183673469387756
27,stock warrants,8.138250682438581
28,biologics licensing application,8.128787878787879
29,resource function,8.125
30,personnel protection,8.107142857142858
31,public offering,8.09775641025641
32,legal proceeding,8.091644204851752
33,months,8.0625
34,lab space,8.05
35,interest income,8.042692939244663
36,allowable investment,8.01
37,month,8.006002824858758
38,state law,8.0
39,months,8.0
40,state taxing authority,8.0
41,months,7.992366412213741
42,month,7.943502824858757
43,month,7.935869237072497
44,innovative therapeutic,7.931432038834951
45,capital resource,7.928571428571429
46,retrospective method,7.928104575163399
47,balance sheet risk,7.917426545086119
48,revenue code,7.91156462585034
49,valuation allowance,7.909698996655519
50,investor relation cost,7.888888888888889
51,preferred stock,7.881611488299386
52,productive discovery,7.870967741935484
53,accounting pronouncement,7.8580246913580245
54,toxicology study,7.854545454545454
55,harbor provision,7.85
56,deferred revenue,7.83656462585034
57,tax position,7.835384615384616
58,data,7.83
59,contract research organization,7.821989528795811
60,discovery stage compound,7.8043010752688176
61,partnership agreement,7.802083333333333
62,equivalent balance,7.767472075109152
63,accounting policy,7.758024691358025
64,biotechnology industry,7.737179487179487
65,call date,7.73469387755102
66,average period,7.73394495412844
67,operating requirement,7.726737967914438
68,letter,7.72551724137931
69,responsibility,7.72551724137931
70,intellectual property,7.716216216216216
71,recurring adjustment,7.714285714285714
72,competitive dynamic,7.703125
73,restricted cash,7.6973844655972625
74,common stock,7.689271090601846
75,therapeutic candidate,7.685514953407816
76,therapeutic candidate,7.685514953407816
77,therapeutic candidate,7.685514953407816
78,luspatercept expired unexercised,7.684210526315789
79,change sensitivity,7.681818181818182
80,significant judgment,7.666666666666666
81,unobservable input,7.666666666666666
82,celgene collaborate,7.65979381443299
83,retrospective basis,7.645276292335116
84,reason,7.625
85,owner source,7.615384615384615
86,interest income interest,7.614121510673234
87,setting body,7.589285714285714
88,preferred stock,7.585058538761362
89,balance sheet arrangement,7.574569402228977
90,muscular dystrophy,7.571428571428571
91,venture investor,7.568927789934355
92,regulatory approval,7.563492063492063
93,payment milestone,7.537588086690599
94,platform technology,7.533333333333333
95,program expenses,7.530266190626835
96,activity,7.522727272727273
97,net loss,7.517397660818713
98,clinical trial,7.5111208173325625
99,balance sheet date,7.509263279779997
100,accounting policy,7.506251641712635
101,holding gain,7.50383631713555
102,diluted equity,7.491869918699187
103,financial statements,7.486322188449847
104,public offering,7.472756410256411
105,tax authority,7.470000000000001
106,significant delay,7.466666666666667
107,stock plan,7.463565808489001
108,state nol carryforwards,7.460000000000001
109,offering price,7.445582497212932
110,preclinical study,7.443706293706294
111,state income tax,7.441264367816093
112,responsibility,7.439802955665025
113,additional compound,7.428382838283829
114,tax asset,7.428333333333333
115,financial statement,7.424893617021276
116,investments debt,7.416666666666668
117,sublicensing revenue,7.41156462585034
118,average assumption,7.4
119,equity debt financing,7.391869918699188
120,additional capital,7.387906647807638
121,common stock,7.3838647175263
122,accounting standards,7.3580246913580245
123,agreement,7.357638888888888
124,development expertise,7.347860601730571
125,clinical trial,7.345858546424621
126,attribute,7.321428571428572
127,income loss,7.309714660213753
128,loss income,7.309714660213753
129,research organization,7.299053748979297
130,valuation allowance,7.294314381270903
131,operating loss,7.289646464646465
132,loss position,7.28507060572278
133,consolidated statement,7.278472906403941
134,exercise price,7.273752012882448
135,potential amount,7.27324973876698
136,year lease extension,7.257202881152461
137,disclosure warrants,7.257142857142857
138,potential project,7.255844155844155
139,patient population,7.25
140,officer insurance premium,7.249019607843138
141,additional capital,7.2450495049504955
142,stock option,7.2433331000209975
143,single digit,7.238095238095238
144,deferred revenue,7.23656462585034
145,regulatory approval,7.23015873015873
146,net,7.225730994152047
147,company,7.22551724137931
148,million wa booked,7.223689694696259
149,substantial doubt,7.214285714285714
150,financial statement,7.210607902735562
151,rent escalation,7.2
152,equivalent cash,7.196689699501848
153,cash cash,7.196689699501848
154,fasb issued asu,7.19350307287094
155,toxicology study,7.1878787878787875
156,equity incentive plan,7.187108013937282
157,therapeutic candidate,7.18056445835831
158,investment policy,7.176666666666666
159,clinical trial,7.169297118833681
160,credit card concentrations,7.163636363636364
161,study material,7.163513619840432
162,molecule ace,7.156716417910448
163,future outcome,7.153225806451613
164,milestone payment,7.147985640207418
165,common stock,7.1382506824385805
166,income taxes,7.13793103448276
167,clinical study,7.1159423633169485
168,accounting guidance,7.1080246913580245
169,unrealized gain,7.10383631713555
170,topic derivatives,7.1
171,accounting policy,7.091358024691358
172,public investor,7.089761123267689
173,based compensation,7.086464968152866
174,clinical trial,7.071626867937622
175,company belief,7.058850574712643
176,credit loss,7.049809896720008
177,deferred revenue,7.047090941639813
178,month term,7.045006584257253
179,licensing expense,7.033084577114428
180,based rsus,7.0252971137521225
181,unrealized loss,7.023134266200233
182,administrative expenses,7.021447568389058
183,funding requirement,7.020872865275143
184,period,7.00409147427496
185,credit risk,7.001543011444001
186,negative evidence,7.0
187,syndrome mds,7.0
188,patent application,6.972283813747229
189,identification method,6.972222222222222
190,therapeutic candidate,6.971229239122101
191,short term,6.961752206603466
192,material loss,6.9579140461215925
193,lease asu requires,6.957472178060414
194,cost,6.947712418300654
195,company,6.945420933193115
196,clinical trial,6.944642740953496
197,net basis,6.9429027113237645
198,subsequent events,6.940476190476191
199,therapeutic candidate,6.935514953407816
200,patent claim,6.926829268292683
201,stock warrant,6.922423344309085
202,quarterly reports,6.921428571428572
203,therapeutic candidate,6.912787680680543
204,debt financing transaction,6.9
205,loss amount,6.884427303891913
206,nol carryforwards,6.880000000000001
207,security law,6.878762886597938
208,investment policy,6.873768115942029
209,potential development,6.873668127538096
210,lease arrangement,6.873529411764706
211,drug product,6.8706812414600815
212,cash flows amount,6.868811657163544
213,expense income net,6.8578577168603445
214,significant expense,6.85530679933665
215,therapeutic candidate,6.838740759859428
216,comprehensive loss,6.838450292397661
217,group,6.833333333333334
218,recently issued standard,6.822494669509595
219,therapeutic candidate,6.8201303380231995
220,milestone payment,6.817980243553345
221,financial statement,6.816197964847364
222,stock option,6.8158277695305935
223,net cash,6.813522904778603
224,year,6.802721088435375
225,december,6.802721088435375
226,cost sharing revenue,6.800453514739229
227,phase trial,6.797365754812564
228,aggregate change,6.785266457680251
229,nol carryforwards research,6.781989528795812
230,government regulation basis,6.772727272727273
231,unvested option,6.769799166350889
232,stock options,6.768607825295723
233,public offering,6.764423076923077
234,specific guidance,6.75
235,development cost,6.749570003439972
236,compound celgene,6.746352954217936
237,revenue service,6.744897959183673
238,drug supply expense,6.744873195000607
239,amount,6.7424682395644275
240,luspatercept expense,6.733961770096884
241,financial asset,6.733941236068896
242,company,6.731135218907401
243,term investments,6.717694235588972
244,tax benefit,6.710000000000001
245,additional fund,6.709335219236209
246,subsequent phase,6.70677136102668
247,collateral,6.706043956043956
248,related service,6.703333333333333
249,clinical trial,6.700281838697856
250,interim period,6.6966778733830985
251,therapeutic candidate,6.685514953407816
252,additional disclosure,6.673620933521924
253,wa approximately million,6.657023028029593
254,risk,6.652857142857142
255,research institution,6.6495757356923635
256,based award,6.648964968152866
257,management,6.648648648648649
258,annual period,6.648230668414155
259,research fee,6.645177934592913
260,service arrangement,6.633333333333333
261,company,6.6302791461412145
262,indemnified party,6.626050420168067
263,actual forfeiture,6.616883116883117
264,product,6.60790273556231
265,compliance research,6.6077038145100975
266,therapeutic candidate,6.605514953407816
267,incur expense,6.588640132669983
268,sale debt security,6.581569904141798
269,therapeutic candidate,6.574403842296704
270,additional activity,6.573332333233324
271,credit,6.568927789934355
272,facility lease obligation,6.565111903347198
273,risk mds,6.559523809523809
274,net proceeds,6.552528379772962
275,reported amount,6.549823165340406
276,comparative period,6.549734427812651
277,rsus,6.535339099828997
278,additional cost,6.522827282728272
279,actual forfeiture,6.521645021645021
280,early adoption,6.514634146341464
281,restricted cash,6.503506914576855
282,manufacture,6.5
283,deferred revenue,6.49635844028333
284,total investment,6.483684210526317
285,luspatercept program,6.481734841081483
286,stock option activity,6.480346087033986
287,financial instrument,6.456560283687943
288,liability,6.43810375453196
289,research,6.425527786204038
290,milestone payment,6.420921420023933
291,share data,6.415393258426966
292,milestone,6.397951976756707
293,term investment,6.394360902255639
294,interest expense,6.393907087936939
295,tiered royalty,6.391304347826087
296,million primarily due,6.386876507883072
297,company,6.384981372753554
298,measurement date,6.378568521425664
299,royalty obligation,6.372785829307569
300,source,6.357808857808858
301,company,6.338451604313673
302,north america celgene,6.326460481099656
303,preclinical program,6.317300637733506
304,outstanding warrant,6.297103696353261
305,miscellaneous expense,6.2970916693130095
306,forfeiture rate,6.293859649122807
307,commercialization,6.291187739463601
308,development activity,6.283408387278357
309,employee,6.272695627958786
310,compensation cost,6.263888888888889
311,market development work,6.257232838689014
312,milestone payment,6.239849209958287
313,company,6.231135218907401
314,company,6.231135218907401
315,cellular growth,6.230769230769231
316,transfer,6.22551724137931
317,annual period,6.219659239842727
318,tax benefit,6.198888888888889
319,significant estimate,6.196078431372548
320,note thereto,6.188888888888888
321,addition asu,6.169657052009994
322,company,6.165917827603053
323,lease expense,6.123280655545801
324,company,6.118374384236453
325,indemnification agreement,6.0997023809523805
326,related note,6.088888888888889
327,totaling million general,6.0776318518299055
328,milestone,6.07202394568418
329,financial condition,6.060348162475822
330,exercise price,6.057924674752952
331,accounting analysis,6.0470490816019264
332,amount,6.020241717376606
333,investment portfolio liquidity,5.976666666666667
334,unvested option,5.965201465201464
335,company,5.960811359026369
336,event,5.92864224137931
337,based rsus,5.913931743805517
338,year research,5.888015939360036
339,warrant liability,5.883773910136801
340,company,5.867898858473694
341,december,5.8427373137438785
342,january celgene,5.8320784586277465
343,development milestone,5.815246426914561
344,development cost,5.808393532851737
345,balance sheet,5.774569402228977
346,share,5.769119455030157
347,research technology company,5.747506770175122
348,executive officer,5.723809523809524
349,current assumption,5.709523809523809
350,section ownership change,5.681818181818182
351,product revenue,5.680181647126935
352,financial condition,5.629703001185499
353,regulatory approval,5.563492063492063
354,luspatercept,5.54421052631579
355,based vesting,5.528985507246377
356,million milestone,5.499683578488308
357,year lease,5.4924969987995205
358,celgene collaboration arrangement,5.45979381443299
359,company,5.448291185159818
360,net decrease,5.3673083567359745
361,reasonable estimate,5.329411764705882
362,additional debt,5.3283828382838285
363,twelve month,5.300645682001614
364,liability,5.291770804546738
365,regulatory authority,5.285714285714286
366,celgene agreement research,5.283866676562134
367,deferred taxes,5.258333333333333
368,human body,5.25
369,collaboration receivables,5.241176470588235
370,preferred stock,5.226849583537481
371,current period,5.192591570669794
372,money market fund,5.146551724137931
373,cash,5.146364057433997
374,common stock,5.1382506824385805
375,public offering,5.097756410256411
376,accounting policy,5.091358024691358
377,ace ace,5.058113686884726
378,drug application,5.045454545454545
379,interest income,5.042692939244663
380,wa due,5.039377289377289
381,company,5.032540269408903
382,clinical trial,5.016071312382067
383,financial statements,4.986322188449848
384,initiation,4.9818181818181815
385,ass performance,4.973684210526316
386,measurement,4.973544973544973
387,nol carryforwards,4.96
388,facility insurance,4.954545454545455
389,innovative therapeutic,4.931432038834951
390,additional capital,4.923620933521923
391,financial resource,4.914893617021276
392,valuation allowance,4.909698996655519
393,capital,4.892857142857142
394,asu requires,4.883942766295707
395,cash,4.873855053832557
396,recently issued,4.858208955223881
397,accounting pronouncement,4.8580246913580245
398,toxicology study,4.8545454545454545
399,comprehensive loss,4.838450292397661
400,tax position,4.835384615384616
401,decision,4.833333333333334
402,government regulation,4.833333333333334
403,data,4.83
404,company,4.827778364646998
405,cash flows,4.822834645669291
406,innovative therapy,4.8125
407,wa expensed,4.808608058608058
408,income net,4.80810647307925
409,net income,4.80810647307925
410,additional program,4.805394332536702
411,consolidated statement,4.795714285714285
412,luspatercept dalantercept,4.78889137737962
413,clinical program,4.7874090477696924
414,financial position,4.780278232405892
415,america gaap,4.766666666666667
416,credit card,4.763636363636364
417,myelodysplastic syndrome,4.75
418,specific task,4.75
419,additional funding,4.7450495049504955
420,investment policy,4.743333333333333
421,policy election,4.733333333333333
422,earnings,4.714285714285714
423,licensed technology,4.7
424,personnel,4.690476190476191
425,therapeutic candidate,4.685514953407816
426,clinical supply,4.672186171402998
427,milestone payment,4.670921420023933
428,risk,4.669642857142858
429,north america,4.666666666666666
430,significant stockholder,4.666666666666666
431,net cash,4.65967675093245
432,tax year,4.653673469387755
433,subsequent phase,4.651215805471125
434,risk,4.642857142857142
435,phase study,4.6388781431334625
436,data,4.633846153846154
437,unvested option,4.631868131868131
438,future payment,4.631486676016831
439,future performance,4.626910016977929
440,expense,4.626674320704172
441,consolidation requirement,4.617647058823529
442,predominantly derived,4.615384615384615
443,primary source,4.615384615384615
444,standard,4.612934362934363
445,stock ownership,4.611464968152866
446,cumulative adjustment,4.6
447,toxicology expense,4.59520578923564
448,collaborative licensing,4.583333333333334
449,facioscapulohumeral dystrophy,4.571428571428571
450,reconciling beginning,4.571428571428571
451,research,4.564846671652955
452,transition method,4.555555555555555
453,legal service,4.5476190476190474
454,medalist trial,4.539007092198581
455,wa offset,4.534761904761904
456,income expense,4.5210156115971865
457,expense income,4.5210156115971865
458,tax expense,4.519751243781094
459,additional activity,4.517776777677768
460,net loss,4.517397660818713
461,option,4.512820512820513
462,modified agreement,4.50796568627451
463,credit risk,4.5064935064935066
464,unrealized gain,4.5038363171355495
465,drug administration,4.5
466,molecule,4.5
467,foreign jurisdiction,4.5
468,similar expression,4.5
469,section item,4.5
470,muscle,4.5
471,litigation,4.5
472,state jurisdiction,4.5
473,key term,4.4943609022556394
474,judgment,4.487179487179487
475,income statement,4.481264367816092
476,clinical utility,4.477064220183486
477,clinical site,4.477064220183486
478,procuring clinical,4.477064220183486
479,financing lease,4.473529411764706
480,single arrangement,4.466666666666667
481,financial condition,4.460348162475822
482,stock option,4.457618814306713
483,financial instrument,4.456560283687943
484,administrative expense,4.4560012437810945
485,proprietary technology,4.45
486,expense,4.449751243781094
487,related expense,4.449751243781094
488,financial asset,4.448226950354609
489,preclinical program,4.444960212201591
490,preclinical study,4.443706293706294
491,company,4.439802955665025
492,beta thalassemia,4.434782608695652
493,expense,4.434366628396479
494,primarily composed,4.433333333333334
495,capital resources,4.428571428571429
496,capital preservation,4.428571428571429
497,financial statement,4.424893617021276
498,related activity,4.422727272727273
499,federal state,4.42
500,generally perpetual,4.411764705882353
501,asc,4.408536585365853
502,personnel expense,4.406894100923951
503,amount,4.395977011494253
504,royalty,4.391304347826087
505,long term,4.384360902255639
506,dalantercept,4.3810444874274665
507,company,4.3802791461412145
508,royalty payment,4.369565217391305
509,standard related,4.364285714285714
510,existing lease,4.359243697478991
511,significant change,4.348484848484849
512,commercial supply,4.342180774748924
513,development payment,4.338941984116301
514,clinical development,4.33774533473457
515,future year,4.336899275839368
516,fully vested,4.333333333333334
517,judgment,4.333333333333334
518,rulesand regulation,4.333333333333334
519,forfeiture,4.333333333333334
520,investment cash,4.3328346456692906
521,additional service,4.3283828382838285
522,milestone,4.325993883792049
523,cash flow,4.322834645669291
524,accounting standard,4.322310405643739
525,adjustment,4.321428571428571
526,wa announced,4.321428571428571
527,incur loss,4.319444444444445
528,existing asset,4.319047619047619
529,loss,4.313888888888888
530,common warrant,4.3109583761562185
531,clinical service,4.310397553516819
532,lead program,4.310344827586206
533,tax benefit,4.3100000000000005
534,amount,4.309134906231095
535,operating loss,4.289646464646465
536,related cost,4.288888888888889
537,existing stockholder,4.285714285714286
538,exercise price,4.273752012882448
539,related disclosure,4.257142857142857
540,estimated amount,4.256503327283727
541,public company,4.246350574712643
542,supply expense,4.244873195000607
543,financial institution,4.2424798239178285
544,date,4.24031185507911
545,incurred loss,4.23937908496732
546,adopting asu,4.235294117647059
547,company,4.231135218907401
548,cellular growth,4.230769230769231
549,company,4.22551724137931
550,company,4.22551724137931
551,company,4.22551724137931
552,wa million,4.223689694696259
553,security,4.22192078133478
554,net proceeds,4.219195046439628
555,valuation methodology,4.217391304347826
556,lower expense,4.2164179104477615
557,indemnified party,4.214285714285714
558,fully offset,4.213333333333333
559,amount,4.199823165340407
560,miscellaneous research,4.196989528795811
561,significant estimate,4.196078431372548
562,development platform,4.194014447884417
563,wa recorded,4.188095238095238
564,promote luspatercept,4.184210526315789
565,operating lease,4.182620320855615
566,collection loss,4.180555555555555
567,loss,4.180555555555555
568,equity investment,4.168536585365853
569,partially offset,4.1657142857142855
570,share data,4.165393258426966
571,operating expense,4.158842152872003
572,net research,4.15883163405897
573,equity,4.158536585365853
574,preclinical activity,4.1573426573426575
575,foreseeable future,4.153225806451613
576,amendment,4.148648648648649
577,remaining life,4.144230769230769
578,risk factors,4.142857142857142
579,current reports,4.142857142857142
580,numerous risk,4.142857142857142
581,risk incident,4.142857142857142
582,risk,4.142857142857142
583,risk,4.142857142857142
584,operating asset,4.142424242424243
585,statement,4.140434782608695
586,incur indebtedness,4.138888888888889
587,indemnification agreement,4.135416666666667
588,investment comparison,4.135
589,delivered pursuant,4.130434782608695
590,net sale,4.126315789473685
591,interim period,4.125249301954527
592,million relating,4.12448334548991
593,equity security,4.117299471963792
594,material,4.115453728661276
595,early adoption,4.114634146341464
596,development funding,4.110681114551084
597,lease obligation,4.110566448801743
598,initial date,4.10969387755102
599,net amortization,4.1095693779904305
600,operating segment,4.109090909090909
601,operating restriction,4.109090909090909
602,expense,4.108574773192859
603,milestone revenue,4.104225176309056
604,aggregate intrinsic,4.103448275862069
605,quarterly report,4.1
606,primarily funded,4.1
607,option,4.096153846153847
608,equity award,4.096036585365853
609,significant uncertainty,4.095238095238095
610,total proceeds,4.0928792569659445
611,initial recognition,4.089285714285714
612,forfeiture rate,4.083333333333334
613,lease commences,4.0735294117647065
614,lease,4.0735294117647065
615,potential benefit,4.067272727272727
616,legal entity,4.067226890756302
617,prior year,4.066026410564225
618,additional million,4.063977294884849
619,material change,4.059176672384219
620,company belief,4.058850574712643
621,incurred costs,4.0588235294117645
622,thereto,4.055555555555555
623,loss,4.055555555555555
624,rare disease,4.052631578947368
625,inflammatory disease,4.052631578947368
626,historical experience,4.05
627,travel expense,4.0497512437810945
628,future product,4.0468428277282085
629,underlying instrument,4.041666666666666
630,accounting change,4.039842873176206
631,accompanying note,4.038314176245211
632,contractual obligation,4.037037037037037
633,existing guidance,4.035714285714286
634,contingent asset,4.033333333333333
635,eligible asset,4.033333333333333
636,future,4.028225806451613
637,subsequent event,4.024553571428571
638,measurement gain,4.0239651416122
639,promotion activity,4.022727272727273
640,future development,4.013906921002697
641,statement,4.01
642,cash change,4.004652827487473
643,approximately million,4.0022611232676875
644,profitability,4.0
645,united states,4.0
646,adjustment,4.0
647,necessarily indicative,4.0
648,resource,4.0
649,collaboration receivables,4.0
650,table,4.0
651,input,4.0
652,technical merit,4.0
653,simplification,4.0
654,physical settlement,4.0
655,litigation,4.0
656,lawsuit,4.0
657,acceleron file,4.0
658,table,4.0
659,variation thereon,4.0
660,shorter timeline,4.0
661,press release,4.0
662,healthy volunteer,4.0
663,profitable depends,4.0
664,investigative site,4.0
665,compliance,4.0
666,exchange,4.0
667,pricing model,4.0
668,readily apparent,4.0
669,accumulated deficit,4.0
670,potentially impair,4.0
671,significantly harm,4.0
672,continued growth,4.0
673,generation solution,4.0
674,neuro inflammation,4.0
675,adopted prospectively,4.0
676,sidney street,4.0
677,measurement date,3.9939531368102794
678,service,3.9871794871794872
679,future partner,3.986559139784946
680,marketable security,3.986540664375716
681,tax examination,3.97
682,study celgene,3.9688847235238986
683,standard shortens,3.9642857142857144
684,short term,3.961752206603465
685,security,3.9587628865979383
686,security,3.9587628865979383
687,preclinical research,3.956604913411196
688,professional fee,3.9565217391304346
689,million due,3.953543174549739
690,ongoing activity,3.9512987012987013
691,incurred cost,3.9477124183006533
692,cost,3.9477124183006533
693,classified statement,3.944782608695652
694,estimated period,3.9444712699179143
695,future sale,3.9426994906621395
696,commercial sale,3.936532507739938
697,industry change,3.9318181818181817
698,purchase share,3.9310072935146856
699,patent,3.926829268292683
700,patent,3.926829268292683
701,outstanding warrant,3.922103696353262
702,independently developing,3.92
703,sale,3.919908466819222
704,material impact,3.9190251572327046
705,year period,3.9176184235161955
706,proprietary knowledge,3.916666666666667
707,historical trend,3.916666666666667
708,annual report,3.9142857142857146
709,collaboration revenue,3.91156462585034
710,development expense,3.9104323583321783
711,celgene,3.90979381443299
712,million compared,3.902261123267688
713,existing agreements,3.901098901098901
714,market acceptance,3.896551724137931
715,milestone event,3.8957855504587156
716,product,3.8936170212765955
717,approved product,3.8936170212765955
718,security,3.89354549529359
719,royalty schedule,3.891304347826087
720,external cost,3.888888888888889
721,cost,3.888888888888889
722,future period,3.8871707605800534
723,development activity,3.8834083872783562
724,premium,3.8823529411764706
725,company,3.879363395225464
726,discovery effort,3.870967741935484
727,ongoing basis,3.8679653679653683
728,commercial license,3.863275039745628
729,joint development,3.8606811145510838
730,assay development,3.8606811145510838
731,development effort,3.8606811145510838
732,footnote disclosure,3.857142857142857
733,party risk,3.8571428571428568
734,share lower,3.8520599250936325
735,rsus vest,3.8516129032258064
736,customers,3.85
737,provision,3.85
738,rent,3.8482142857142856
739,sotatercept including,3.8471794871794875
740,underlying option,3.8461538461538463
741,vested option,3.8461538461538463
742,option,3.8461538461538463
743,recognized based,3.8380952380952382
744,future change,3.8350439882697946
745,management belief,3.8333333333333335
746,collaboration partner,3.833333333333333
747,service,3.833333333333333
748,profit institution,3.8275862068965516
749,amortization expense,3.822478516508367
750,research focus,3.8219895287958114
751,outsourced research,3.8219895287958114
752,external research,3.8219895287958114
753,continued research,3.8219895287958114
754,factor,3.8205128205128203
755,future trend,3.81989247311828
756,presented separately,3.8157894736842106
757,manufacturing preclinical,3.809615384615385
758,collaboration agreement,3.802083333333333
759,consulting agreement,3.802083333333333
760,period,3.8006116207951073
761,collaboration arrangement,3.8
762,rentable office,3.8
763,accounting analysis,3.797049081601927
764,sale profit,3.7894736842105265
765,revenue,3.78656462585034
766,applicable warrant,3.7841726618705036
767,temporary impairment,3.782608695652174
768,impairment compliance,3.782608695652174
769,additional information,3.780763790664781
770,potential impact,3.7689393939393936
771,primarily attributable,3.7666666666666666
772,pay annually,3.761904761904762
773,product development,3.7542981358276792
774,applicable guidance,3.75
775,substantially accurate,3.75
776,matter,3.75
777,reduced rate,3.75
778,efficiently identify,3.75
779,scope rate,3.75
780,development cost,3.749570003439972
781,sale security,3.7482365708084644
782,favorable term,3.744360902255639
783,term,3.744360902255639
784,actual result,3.742424242424242
785,milestone,3.738115095913261
786,period,3.7339449541284404
787,period,3.7339449541284404
788,comparable period,3.7339449541284404
789,operations,3.7333333333333334
790,discovery development,3.7316488564865673
791,share amount,3.731370269921219
792,business,3.730434782608696
793,company doe,3.7255172413793103
794,company,3.7255172413793103
795,company,3.7255172413793103
796,company adjusts,3.7255172413793103
797,company,3.7255172413793103
798,company,3.7255172413793103
799,company,3.7255172413793103
800,company,3.7255172413793103
801,company,3.7255172413793103
802,company,3.7255172413793103
803,company,3.7255172413793103
804,company,3.7255172413793103
805,leading company,3.7255172413793103
806,company,3.7255172413793103
807,company file,3.7255172413793103
808,operations,3.725
809,warrant,3.7189552705661555
810,january expense,3.7164179104477615
811,collaboration license,3.7162162162162162
812,licensable license,3.7162162162162162
813,level measurement,3.7138047138047137
814,trigger,3.703125
815,event,3.703125
816,unanticipated event,3.703125
817,activity,3.6893939393939394
818,cost,3.688888888888889
819,share issuable,3.6853932584269664
820,product sale,3.683090705487122
821,generally subject,3.6796218487394956
822,manufacturing capability,3.675
823,related subject,3.6678571428571427
824,differ materially,3.666666666666667
825,exchange commission,3.666666666666667
826,generated exclusively,3.666666666666667
827,optional contribution,3.666666666666667
828,development progress,3.6606811145510836
829,celgene corporation,3.65979381443299
830,celgene,3.65979381443299
831,myelofibrosis celgene,3.65979381443299
832,advance ace,3.656716417910448
833,pay royalty,3.653209109730849
834,revenue,3.649659863945578
835,revenue,3.649659863945578
836,research institution,3.6495757356923635
837,option agreement,3.6482371794871797
838,annual period,3.648230668414155
839,current expectation,3.642857142857143
840,royalty rate,3.641304347826087
841,deposit concentrations,3.6307692307692307
842,potential commercialization,3.6295715778474396
843,incurred million,3.6277513193461193
844,period,3.616297895304911
845,prior period,3.616297895304911
846,period,3.6139449541284403
847,continuing operation,3.613799283154122
848,company,3.607870182555781
849,thousand unaudited,3.607142857142857
850,asset liability,3.606148867313916
851,developing luspatercept,3.6042105263157893
852,operations,3.6
853,amount,3.5914315569487982
854,amortized cost,3.5888888888888886
855,warrant agreement,3.586255995203837
856,company,3.5826600985221675
857,activity,3.5782828282828287
858,liability,3.5728155339805827
859,million naming,3.5689277899343548
860,luspatercept offset,3.5642105263157893
861,costs,3.5555555555555554
862,substantially completed,3.55
863,period,3.549734427812651
864,sufficient amount,3.545977011494253
865,adversely impact,3.541666666666667
866,reasonable period,3.5339449541284402
867,company,3.52551724137931
868,license agreement,3.5182995495495497
869,january topic,3.5166666666666666
870,thing statement,3.51
871,amortization period,3.506672226855713
872,fee,3.5019762845849804
873,management,3.5
874,transfer good,3.5
875,concern,3.5
876,hedging contracts,3.5
877,considered probable,3.5
878,word,3.5
879,potentially begin,3.5
880,amendment doe,3.5
881,retrospectively adjusted,3.5
882,business product,3.493617021276596
883,equity securities,3.4918699186991873
884,luspatercept agreement,3.4862938596491224
885,accounting treatment,3.4770723104056436
886,investment liquidity,3.4766666666666666
887,agreement celgene,3.461877147766323
888,celgene agreement,3.461877147766323
889,dalantercept,3.4589665653495443
890,lowest level,3.4545454545454546
891,level input,3.4545454545454546
892,estimated fair,3.451702786377709
893,developing estimate,3.449411764705882
894,consolidation analysis,3.4390243902439024
895,business partner,3.4333333333333336
896,luspatercept dalantercept,3.4288913773796192
897,uncertainty,3.428571428571429
898,uncertainty,3.428571428571429
899,matter,3.416666666666667
900,mid range,3.4117647058823533
901,commercialization marketing,3.402298850574713
902,commercialization,3.402298850574713
903,ace,3.4013972689742777
904,original date,3.4013605442176873
905,commercialize luspatercept,3.398496240601504
906,party cros,3.380952380952381
907,reimburse collaborator,3.375
908,company record,3.368374384236453
909,company,3.368374384236453
910,entity,3.3529411764705883
911,company,3.3505172413793103
912,recognize revenue,3.34906462585034
913,aggregate fair,3.3446247464503043
914,celgene,3.3440043407487794
915,cros,3.341666666666667
916,license,3.3412162162162162
917,ace,3.3409269442262373
918,estimation process,3.333333333333333
919,collaboration reimbursement,3.333333333333333
920,strategy target,3.333333333333333
921,unknown factor,3.333333333333333
922,adversely affect,3.333333333333333
923,reasonable estimate,3.329411764705882
924,commercial operation,3.316413662239089
925,ace ace,3.3134328358208953
926,luspatercept agreements,3.299595141700405
927,manufacture luspatercept,3.2953216374269005
928,underwriting discount,3.2941176470588234
929,commercialization cost,3.2911877394636013
930,identifies area,3.2857142857142856
931,developing sotatercept,3.2800000000000002
932,outcome timing,3.2727272727272725
933,potentially subject,3.267857142857143
934,read carefully,3.25
935,bring forward,3.25
936,temporary difference,3.25
937,annual limitation,3.2476190476190476
938,earnings,3.2411764705882353
939,duration cost,3.2222222222222223
940,patent expiration,3.2125435540069684
941,research,3.206604913411196
942,economic circumstance,3.2
943,premium,3.1900452488687785
944,proceeds,3.1680672268907566
945,sotatercept agreement,3.1620833333333334
946,fair market,3.1377281947261664
947,extent,3.1315789473684212
948,december commitments,3.119047619047619
949,support development,3.1106811145510838
950,anemia celgene,3.104238258877434
951,recorded million,3.102261123267688
952,dalantercept,3.101823708206687
953,business enterprise,3.1
954,classification change,3.0984848484848486
955,contemplate continue,3.096774193548387
956,time period,3.0962637947081504
957,commercialize sotatercept,3.0742857142857143
958,update change,3.0568181818181817
959,completion cost,3.0555555555555554
960,company,3.0332095490716178
961,million decrease,3.030466251472816
962,date,3.020408163265306
963,sotatercept celgene,3.01979381443299
964,gain,3.014705882352941
965,identify forward,3.0
966,original maturity,2.9824561403508776
967,acquire sell,2.9696969696969697
968,partner ability,2.9375
969,effective date,2.9346938775510205
970,increase substantially,2.926
971,company,2.907335423197492
972,company,2.8921839080459772
973,treat patient,2.875
974,result differ,2.8636363636363638
975,issuance date,2.822929171668667
976,anemia,2.8194444444444446
977,estimate,2.815126050420168
978,discount,2.7941176470588234
979,celgene responsible,2.791372761801411
980,ace,2.781716417910448
981,ace,2.753490611458835
982,nature,2.75
983,million increase,2.7449277899343545
984,expenses,2.742857142857143
985,long,2.64
986,fair presentation,2.62579185520362
987,requirement,2.6176470588235294
988,fasb,2.6
989,individual customer,2.5846153846153843
990,beginning,2.5714285714285716
991,equivalent,2.5510204081632653
992,application,2.5454545454545454
993,trial,2.5390070921985815
994,state,2.5
995,additional,2.495049504950495
996,clinical,2.477064220183486
997,tax,2.47
998,raise,2.4642857142857144
999,rsus,2.4516129032258065
1000,approximately,2.433333333333333
1001,financing,2.4
1002,related,2.4
1003,permitted,2.4
1004,interim,2.391304347826087
1005,due,2.3846153846153846
1006,compensation,2.375
1007,credit,2.3636363636363638
1008,issued,2.3582089552238807
1009,accounting,2.3580246913580245
1010,price,2.347826086956522
1011,investments,2.3333333333333335
1012,forfeiture,2.3333333333333335
1013,phase,2.3297872340425534
1014,cash,2.322834645669291
1015,subsequent,2.3214285714285716
1016,require,2.3214285714285716
1017,candidate,2.3165829145728645
1018,study,2.309090909090909
1019,held,2.263157894736842
1020,unaudited,2.25
1021,asc,2.25
1022,industry,2.25
1023,mds,2.25
1024,effect,2.25
1025,space,2.25
1026,purchase,2.245614035087719
1027,asu,2.235294117647059
1028,potential,2.227272727272727
1029,method,2.2222222222222223
1030,valuation,2.217391304347826
1031,estimated,2.210526315789474
1032,total,2.210526315789474
1033,technology,2.2
1034,milestone,2.1926605504587156
1035,year,2.183673469387755
1036,loss,2.1805555555555554
1037,equity,2.158536585365854
1038,provided,2.1538461538461537
1039,expensed,2.1538461538461537
1040,future,2.153225806451613
1041,risk,2.142857142857143
1042,incur,2.138888888888889
1043,outstanding,2.1379310344827585
1044,preclinical,2.1346153846153846
1045,included,2.1333333333333333
1046,operating,2.109090909090909
1047,aggregate,2.103448275862069
1048,based,2.1
1049,lease,2.073529411764706
1050,vesting,2.066666666666667
1051,june,2.0625
1052,incurred,2.0588235294117645
1053,conduct,2.0555555555555554
1054,expense,2.0497512437810945
1055,amount,2.045977011494253
1056,condition,2.0454545454545454
1057,instrument,2.0416666666666665
1058,obligation,2.037037037037037
1059,asset,2.033333333333333
1060,plan,2.0285714285714285
1061,activity,2.022727272727273
1062,investment,2.01
1063,statement,2.01
1064,regulate,2.0
1065,growth,2.0
1066,compliance,2.0
1067,identified,2.0
1068,carried,2.0
1069,accumulated,2.0
1070,evidence,2.0
1071,collateral,2.0
1072,experienced,2.0
1073,receivables,2.0
1074,group,2.0
1075,probable,2.0
1076,transfer,2.0
1077,input,2.0
1078,adopted,2.0
1079,identification,2.0
1080,adjustment,2.0
1081,obtain,2.0
1082,collaboration,2.0
1083,september,2.0
1084,negative,2.0
1085,reflect,2.0
1086,underlying,2.0
1087,built,2.0
1088,approved,2.0
1089,potentially,2.0
1090,outcome,2.0
1091,judgment,2.0
1092,critical,2.0
1093,utilize,2.0
1094,defending,2.0
1095,ownership,2.0
1096,section,2.0
1097,march,1.9923664122137406
1098,standard,1.9642857142857142
1099,security,1.958762886597938
1100,fee,1.9565217391304348
1101,basis,1.9393939393939394
1102,award,1.9375
1103,classified,1.934782608695652
1104,ongoing,1.9285714285714286
1105,patent,1.9268292682926829
1106,exercise,1.9259259259259258
1107,developing,1.92
1108,federal,1.92
1109,annual,1.9142857142857144
1110,revenue,1.91156462585034
1111,initiation,1.9090909090909092
1112,market,1.896551724137931
1113,product,1.8936170212765957
1114,royalty,1.891304347826087
1115,cost,1.8888888888888888
1116,develop,1.8888888888888888
1117,excess,1.8888888888888888
1118,premium,1.8823529411764706
1119,prior,1.8823529411764706
1120,proceeds,1.8823529411764706
1121,expects,1.8823529411764706
1122,offset,1.88
1123,generate,1.875
1124,general,1.872340425531915
1125,discovery,1.8709677419354838
1126,development,1.8606811145510835
1127,disclosure,1.8571428571428572
1128,provision,1.85
1129,topic,1.85
1130,option,1.8461538461538463
1131,benefit,1.84
1132,service,1.8333333333333333
1133,partner,1.8333333333333333
1134,institution,1.8275862068965518
1135,research,1.8219895287958114
1136,presented,1.8157894736842106
1137,agreement,1.8020833333333333
1138,reasonable,1.8
1139,arrangement,1.8
1140,progress,1.8
1141,experience,1.8
1142,completed,1.8
1143,sale,1.7894736842105263
1144,warrant,1.7841726618705036
1145,impairment,1.7826086956521738
1146,amortization,1.7727272727272727
1147,life,1.7692307692307692
1148,gain,1.7647058823529411
1149,pay,1.7619047619047619
1150,guidance,1.75
1151,rate,1.75
1152,substantially,1.75
1153,anticipated,1.75
1154,identify,1.75
1155,fund,1.75
1156,substantial,1.75
1157,dalantercept,1.7446808510638299
1158,term,1.744360902255639
1159,recognized,1.7380952380952381
1160,date,1.7346938775510203
1161,period,1.7339449541284404
1162,company,1.7255172413793103
1163,license,1.7162162162162162
1164,party,1.7142857142857142
1165,commercialize,1.7142857142857142
1166,recognition,1.7142857142857142
1167,event,1.703125
1168,amortized,1.7
1169,share,1.6853932584269662
1170,luspatercept,1.6842105263157894
1171,change,1.6818181818181819
1172,manufacturing,1.675
1173,january,1.6666666666666667
1174,commission,1.6666666666666667
1175,transaction,1.6666666666666667
1176,knowledge,1.6666666666666667
1177,original,1.6666666666666667
1178,funded,1.6666666666666667
1179,seek,1.6666666666666667
1180,generated,1.6666666666666667
1181,cros,1.6666666666666667
1182,trend,1.6666666666666667
1183,differ,1.6666666666666667
1184,investing,1.6666666666666667
1185,celgene,1.6597938144329898
1186,ace,1.6567164179104477
1187,current,1.6428571428571428
1188,agreed,1.6428571428571428
1189,record,1.6428571428571428
1190,acquire,1.6363636363636365
1191,includes,1.625
1192,december,1.619047619047619
1193,agreements,1.6153846153846154
1194,manufacture,1.6111111111111112
1195,operations,1.6
1196,business,1.6
1197,liability,1.5728155339805825
1198,low,1.5714285714285714
1199,million,1.5689277899343546
1200,include,1.5625
1201,note,1.5555555555555556
1202,performed,1.5555555555555556
1203,defined,1.5454545454545454
1204,carrying,1.5454545454545454
1205,impact,1.5416666666666667
1206,recorded,1.5333333333333334
1207,estimate,1.5294117647058822
1208,management,1.5
1209,enterprise,1.5
1210,money,1.5
1211,nature,1.5
1212,considered,1.5
1213,contracts,1.5
1214,receive,1.5
1215,good,1.5
1216,concern,1.5
1217,adjusted,1.5
1218,examination,1.5
1219,word,1.5
1220,thing,1.5
1221,patient,1.5
1222,allocate,1.5
1223,sufficient,1.5
1224,begin,1.5
1225,commitments,1.5
1226,amendment,1.5
1227,continues,1.5
1228,liquidity,1.4666666666666666
1229,decrease,1.4615384615384615
1230,level,1.4545454545454546
1231,anemia,1.4444444444444444
1232,analysis,1.4390243902439024
1233,recognize,1.4375
1234,uncertainty,1.4285714285714286
1235,classification,1.4166666666666667
1236,discussed,1.4166666666666667
1237,adoption,1.4146341463414633
1238,range,1.411764705882353
1239,employee,1.4074074074074074
1240,commercialization,1.4022988505747127
1241,assumption,1.4
1242,vest,1.4
1243,sublease,1.4
1244,presentation,1.3846153846153846
1245,conducting,1.3846153846153846
1246,individual,1.3846153846153846
1247,reimburse,1.375
1248,update,1.375
1249,treat,1.375
1250,time,1.3623188405797102
1251,sotatercept,1.36
1252,thousand,1.3571428571428572
1253,evaluating,1.3571428571428572
1254,entity,1.3529411764705883
1255,expected,1.3333333333333333
1256,affect,1.3333333333333333
1257,factor,1.3333333333333333
1258,process,1.3333333333333333
1259,sell,1.3333333333333333
1260,duration,1.3333333333333333
1261,strategy,1.3333333333333333
1262,reimbursement,1.3333333333333333
1263,securities,1.3333333333333333
1264,limitation,1.3333333333333333
1265,attributable,1.3333333333333333
1266,maturity,1.3157894736842106
1267,paid,1.3076923076923077
1268,discount,1.2941176470588236
1269,addition,1.2857142857142858
1270,area,1.2857142857142858
1271,make,1.2857142857142858
1272,expiration,1.2857142857142858
1273,information,1.2857142857142858
1274,received,1.2857142857142858
1275,grant,1.2857142857142858
1276,timing,1.2727272727272727
1277,subject,1.2678571428571428
1278,read,1.25
1279,realized,1.25
1280,amended,1.25
1281,difference,1.25
1282,forward,1.25
1283,support,1.25
1284,fair,1.2411764705882353
1285,half,1.2352941176470589
1286,deposit,1.2307692307692308
1287,customer,1.2
1288,circumstance,1.2
1289,effective,1.2
1290,medicine,1.2
1291,result,1.196969696969697
1292,determined,1.1818181818181819
1293,base,1.1818181818181819
1294,increase,1.176
1295,operation,1.1693548387096775
1296,reference,1.1666666666666667
1297,changed,1.1666666666666667
1298,investigational,1.1666666666666667
1299,completion,1.1666666666666667
1300,invested,1.1666666666666667
1301,designed,1.1538461538461537
1302,modification,1.1428571428571428
1303,reduction,1.1428571428571428
1304,cancer,1.1428571428571428
1305,extent,1.131578947368421
1306,responsible,1.131578947368421
1307,measured,1.125
1308,treatment,1.119047619047619
1309,ability,1.1041666666666667
1310,continue,1.096774193548387
1311,issuance,1.088235294117647
1312,part,1.0666666666666667
1313,mechanism,1.0
1314,repair,1.0
1315,cell,1.0
1316,tissue,1.0
1317,combining,1.0
1318,action,1.0
1319,limited,1.0
1320,relying,1.0
1321,prepared,1.0
1322,conformity,1.0
1323,meant,1.0
1324,refer,1.0
1325,found,1.0
1326,opinion,1.0
1327,conjunction,1.0
1328,discussion,1.0
1329,results,1.0
1330,form,1.0
1331,detailed,1.0
1332,estimates,1.0
1333,preparation,1.0
1334,selecting,1.0
1335,control,1.0
1336,volatility,1.0
1337,representative,1.0
1338,yield,1.0
1339,select,1.0
1340,fall,1.0
1341,turn,1.0
1342,made,1.0
1343,preparing,1.0
1344,determination,1.0
1345,recoverability,1.0
1346,component,1.0
1347,evaluation,1.0
1348,manage,1.0
1349,day,1.0
1350,acquisition,1.0
1351,bank,1.0
1352,approximates,1.0
1353,reevaluates,1.0
1354,designation,1.0
1355,hold,1.0
1356,accretion,1.0
1357,dividend,1.0
1358,recoverable,1.0
1359,intent,1.0
1360,required,1.0
1361,recovery,1.0
1362,severity,1.0
1363,end,1.0
1364,summary,1.0
1365,certificate,1.0
1366,concentration,1.0
1367,quality,1.0
1368,exposure,1.0
1369,creditworthiness,1.0
1370,believed,1.0
1371,measurements,1.0
1372,hierarchy,1.0
1373,manner,1.0
1374,deeply,1.0
1375,elected,1.0
1376,elect,1.0
1377,measure,1.0
1378,accordance,1.0
1379,consideration,1.0
1380,fact,1.0
1381,reconciliation,1.0
1382,number,1.0
1383,calculation,1.0
1384,basic,1.0
1385,excluded,1.0
1386,inclusion,1.0
1387,consists,1.0
1388,occur,1.0
1389,supersedes,1.0
1390,reflects,1.0
1391,august,1.0
1392,evaluate,1.0
1393,existence,1.0
1394,february,1.0
1395,respect,1.0
1396,perform,1.0
1397,determine,1.0
1398,consolidate,1.0
1399,type,1.0
1400,november,1.0
1401,replaces,1.0
1402,accounted,1.0
1403,lessee,1.0
1404,calculated,1.0
1405,assessing,1.0
1406,aspect,1.0
1407,connection,1.0
1408,consummated,1.0
1409,detail,1.0
1410,place,1.0
1411,july,1.0
1412,exercisable,1.0
1413,accreted,1.0
1414,redemption,1.0
1415,earlier,1.0
1416,ordinary,1.0
1417,pending,1.0
1418,threatened,1.0
1419,met,1.0
1420,payable,1.0
1421,agrees,1.0
1422,copyright,1.0
1423,execution,1.0
1424,unlimited,1.0
1425,indication,1.0
1426,exclusive,1.0
1427,overseeing,1.0
1428,start,1.0
1429,food,1.0
1430,assurance,1.0
1431,paying,1.0
1432,buy,1.0
1433,noted,1.0
1434,reimbursed,1.0
1435,represent,1.0
1436,deliverable,1.0
1437,payments,1.0
1438,obligated,1.0
1439,owe,1.0
1440,percentage,1.0
1441,reach,1.0
1442,represents,1.0
1443,accelerated,1.0
1444,occurrence,1.0
1445,achievement,1.0
1446,positive,1.0
1447,realizability,1.0
1448,history,1.0
1449,deemed,1.0
1450,anticipate,1.0
1451,vision,1.0
1452,case,1.0
1453,intended,1.0
1454,enter,1.0
1455,degree,1.0
1456,quickly,1.0
1457,relate,1.0
1458,depend,1.0
1459,longer,1.0
1460,caution,1.0
1461,guarantee,1.0
1462,operate,1.0
1463,speak,1.0
1464,undertake,1.0
1465,understand,1.0
1466,advised,1.0
1467,consult,1.0
1468,website,1.0
1469,overview,1.0
1470,discovering,1.0
1471,field,1.0
1472,focused,1.0
1473,partnered,1.0
1474,complication,1.0
1475,commercialized,1.0
1476,wholly,1.0
1477,volume,1.0
1478,implemented,1.0
1479,accelerating,1.0
1480,nominated,1.0
1481,expect,1.0
1482,distribution,1.0
1483,unable,1.0
1484,needed,1.0
1485,fail,1.0
1486,discontinue,1.0
1487,description,1.0
1488,acquiring,1.0
1489,maintenance,1.0
1490,obtaining,1.0
1491,vendor,1.0
1492,certainty,1.0
1493,succeed,1.0
1494,variety,1.0
1495,receipt,1.0
1496,variable,1.0
1497,enrollment,1.0
1498,inception,1.0
1499,expensing,1.0
1500,track,1.0
1501,assign,1.0
1502,salary,1.0
1503,headcount,1.0
1504,payroll,1.0
1505,determining,1.0
1506,marking,1.0
1507,mix,1.0
1508,combination,1.0
1509,view,1.0
1510,implementation,1.0
1511,began,1.0
1512,invest,1.0
1513,closing,1.0
1514,pursue,1.0
1515,dilution,1.0
1516,senior,1.0
1517,covenant,1.0
1518,restrict,1.0
1519,competitiveness,1.0
1520,prospect,1.0
1521,forecast,1.0
1522,adequate,1.0
1523,vary,1.0
1524,prove,1.0
1525,wrong,1.0
1526,establish,1.0
1527,characteristic,1.0
1528,caused,1.0
1529,hiring,1.0
1530,filing,1.0
1531,enforcing,1.0
1532,realize,1.0
1533,greater,1.0
1534,portion,1.0
1535,utilization,1.0
1536,lost,1.0
1537,commitment,1.0
1538,intend,1.0
1539,complete,1.0
1540,depreciation,1.0
1541,disclosed,1.0
1542,applied,1.0
1543,relates,1.0
1544,collected,1.0
1545,consistent,1.0
1546,definition,1.0
1547,applying,1.0
1548,mri,1.0
1549,expanding,1.0
1550,october,1.0
1551,extend,1.0
1552,landlord,1.0
1553,build,1.0
1554,discontinued,1.0
